The global influenza diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of chronic diseases such as diabetes, heart disease, and blood disorders as well as the development of technologically advanced influenza diagnostic tests.
Influenza, also known as the flu disease, is a type of viral infection of the upper respiratory areas caused by the influenza virus. The seasonal influenza virus is divided into three types: Type A, B, and C. These three types are distinguished by two main surface proteins: hemagglutinin (HA) and neuraminidase (NA). Various serotypes can be identified based on variations in these surface proteins, which determine the virus's antibody response.
Influenza is a highly contagious and communicable disease that it can be easily spread in public areas from infected patients who act as carriers of the virus. The severity of the disease varies due to different temperatures, or locations or regions experiencing seasonal influenza outbreaks. In tropical areas, where influenza is likely to occur year-round and managing or treating of the disease is difficult. Pregnant women, infants, the elderly people with chronic medical conditions are among those who are at high risk for influenza.
Various antiviral medications are used to treat influenza, which helps to reduce complications and fatalities such as death. However, due to drug resistance, most antiviral medications are found unsuccessful in most of the patients. As a result, demand for vaccines and medicines are rising to treat and cure the disease, which aid to boost the demand for diagnostic procedures.
Market Trends, Drivers, Restraints, and Opportunities
- Rising geriatric population who are vulnerable to a wide range of infectious diseases and increasing number of flu diseases among women are key drivers for the market expansion.
- Several government measures to combat influenza and favorable regulatory policies that encourage the development of vaccines and drugs for the disease treatment are projected to fuel the market growth during the forecast period.
- Advent of technologically advanced influenza diagnostic devices and wide drug discovery activities in clinical laboratories are driving the market growth.
- Requirement of the high standardization of research findings and the high installment cost of diagnostic instruments are key challenges that can hamper the market growth.
- Ongoing R&D programs and growing demand for easy management and treatment solution for the disease are projected to create significant opportunities for the market players.
Scope of Influenza Diagnostics Market Report
The report on the global influenza diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Influenza Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Test Types (RIDT, RT-PCR, Cell Culture, and Others) and End-users (Hospitals, Laboratories, and POCT)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Roche Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific; Alere, and Quidel Corporation.
Influenza Diagnostics Market Segment Insights
RIDT segment is projected to hold a key market share
Based on test types, the global influenza diagnostic market is divided into RIDT, RT-PCR, cell culture, and others.
The RIDT segment is projected to hold a key share of the market during the forecast period owing to the wide adoption of the testing type for diagnosis of influenza types A and B. The specimens of diseases types can be detected qualitatively using these methods and these tests offer fast results. The other segment accounted for a large share of the market due to the precision and accuracy that immunofluorescence and serology provide.
The cell culture segment, however, is anticipated to expand at a robust growth rate in the coming years owing to rising adoption as a key diagnostic tool. When determining the prevalence rate of a disease, cell culture is commonly used as a reference tool. Cell culture offers precise statistics as well as the ability to differentiate between different types of influenza viruses. These experiments are usually carried out in laboratories and the results normally take several days to arrive varying from 3 to 10 days depending on the circumstances.
Positive predictive value (PPV) and negative predictive value (NPV) are provided by the diagnostic tool. In recent years, cell culture-derived influenza vaccines have been developed to meet the need for better influenza defense.
Meanwhile, the RT-PCR segment is expected to register a high CAGR during the forecast period. RT-PCRs produce results in a fair amount of time, ranging from 20 minutes to less than 2 hours. Both viable and nonviable influenza viruses can be detected using these tests.
The demand for RT-PCR tests is fueled by the fact that they are potentially effective tests that can determine the influenza type A and B with a very low risk of false-positive or negative results. The disadvantage of RT-PCR is that it is more costly than other influenza studies, and certain tests have yet to obtain FDA approval in the US.
POCT is expected to exhibit a robust market growth
On the basis of end-users, the market is divided into hospitals, laboratories, and POCT.
The POCT segment is expected to exhibit a robust market growth rate in the coming years due to factors such as their ease of use and user-friendly since using these POCT diagnostic devices do not need much expertise beyond basic operational knowledge. With the introduction of technologically advanced POCT, the physicians' dependence on these tests are quite visible. The majority of CLIA-waived RIDTs are used in point-of-care (POC) environments.
The increasing use of influenza diagnostic testing kits can be attributed to POCT. In the near future, new technical advances in POC test kits due to shorter processing times and error-free performance, are expected to fuel the demand even further.
The laboratories segment, on the other hand, is expected to rise at a steady CAGR during the targeted period due to introduction of long-term laboratory facilities and are wide adopted in clinics and hospitals. The real-time RT-PCR technique is commonly used in the laboratory diagnosis and the segment has many advantages such as quick results, highly sensitive, precise, flexible, and cost-effective.
Meanwhile, hospitals serve as the main research centres in underdeveloped and developing countries that lack access to rapid diagnostic tests. As a result, the hospital segment is expected to register a substantial growth rate in the coming years owing to wide establishment of advanced diagnostic devices.
Asia Pacific is anticipated to represent a major market share
In terms of regions, the influenza diagnostic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
The market in Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period due to high technological advancement in the field as well as rising healthcare spending. Due to factors such as high population density and rising disease burden in the region, Asia Pacific is expected to constitute a large market share in the coming years.
Human infection with avian influenza A (H5NI), which resulted in an influenza pandemic, is one of the most alarming aspects of influenza in Asia. There is increasing concern and countries are actively engaged in taking preventative measures to reduce disease incidence.
For example, the United States Centers for Disease Control and Prevention (CDC) has reached a cooperative agreement with the South-East Asian Region (SEAR) to finance non-researched bilateral influenza as a measure to respond to avian, seasonal, and pandemic influenza.
Meanwhile, the market in North America is projected to account for a significant market share during the forecast period due to high prevalence of the flu disease. Moreover, early acceptance of advanced technology for diagnostic devices and favorable government regulations related to the disease prevention present another key factor pushing the regional market growth.
For instance, the CDC aggressively takes preventive steps to curb the disease through its national influenza surveillance system by assessing the seriousness of the disease. Additionally, the widespread availability of rapid diagnostic tests (RDTs) in the US has increased the diagnostic acceptance rates. High public knowledge and the availability of a wide variety of diagnostic procedures in the region help to boost the market expansion in North America.
The global influenza diagnostic market has been segmented on the basis of
- Cell Culture
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the influenza diagnostic market include Roche Diagnostics, Becton, Dickinson and Company, Thermo Fisher Scientific, Alere, and Quidel Corporation among others.
The companies are actively working to create diagnostic devices that are both cost-effective and technologically advanced to ensure effective care of patients. For example, in October 2014, Alere announced a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services to develop diagnostic countermeasures for the influenza virus.
Roche obtained FDA approval and a CLIA waiver for the cobas Influenza A/B & RSV test in 2016. The test was designed to work in conjunction with the cobas Liat System, with an aim of aids in the molecular testing of flu A/B, strep A, and RSV.